Korro Bio plans a reverse merger with Frequency Therapeutics to fund clinical studies of its lead candidate, designed to treat alpha-1 antitrypsin deficiency (AATD) in the liver.
Korro Bio plans a reverse merger with Frequency Therapeutics to fund clinical studies of its lead candidate, designed to treat alpha-1 antitrypsin deficiency (AATD) in the liver.
Alpha-1 antitrypsin deficiency is a genetic disorder that can lead to liver disease and lung complications. Currently, there are limited treatment options available for this condition, making the development of new therapies a crucial endeavor. Korro Bio’s lead candidate holds promise in addressing this unmet medical need.